264 related articles for article (PubMed ID: 29656449)
1. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
[TBL] [Abstract][Full Text] [Related]
2. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Brennan AT; Maskew M; Ive P; Shearer K; Long L; Sanne I; Fox MP
J Int AIDS Soc; 2013 Nov; 16(1):18794. PubMed ID: 24256692
[TBL] [Abstract][Full Text] [Related]
3. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
4. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
[TBL] [Abstract][Full Text] [Related]
5. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
[TBL] [Abstract][Full Text] [Related]
6. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
[TBL] [Abstract][Full Text] [Related]
7. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
[TBL] [Abstract][Full Text] [Related]
8. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa.
Brennan AT; Jamieson L; Crowther NJ; Fox MP; George JA; Berry KM; Stokes A; Maskew M; Sanne I; Long L; Cassim N; Rosen S
PLoS One; 2018; 13(10):e0204020. PubMed ID: 30281618
[TBL] [Abstract][Full Text] [Related]
10. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Brennan AT; Shearer K; Maskew M; Long L; Sanne I; Fox MP
Trop Med Int Health; 2014 May; 19(5):490-8. PubMed ID: 24589363
[TBL] [Abstract][Full Text] [Related]
11. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Abgrall S; Ingle SM; May MT; Costagliola D; Mercie P; Cavassini M; Reekie J; Samji H; Gill MJ; Crane HM; Tate J; Sterling TR; Antinori A; Reiss P; Saag MS; Mugavero MJ; Phillips A; Manzardo C; Wasmuth JC; Stephan C; Guest JL; Gomez Sirvent JL; Sterne JA;
AIDS; 2013 Mar; 27(5):803-13. PubMed ID: 23719350
[TBL] [Abstract][Full Text] [Related]
12. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
13. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
[TBL] [Abstract][Full Text] [Related]
14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
15. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Shearer K; Fox MP; Maskew M; Berhanu R; Long L; Sanne I
PLoS One; 2013; 8(8):e71719. PubMed ID: 23940782
[TBL] [Abstract][Full Text] [Related]
16. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
[TBL] [Abstract][Full Text] [Related]
17. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
19. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
20. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
Steegen K; Levin L; Ketseoglou I; Bronze M; Papathanasopoulos MA; Carmona S; Stevens W
PLoS One; 2014; 9(5):e97067. PubMed ID: 24816790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
